Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838578 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00838578 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 65 participants.
The verdict
NCT00838578, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorectal cancer.
Interventions
- DRUG Irinotecan
- BIOLOGICAL KRN330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838578
The ClinicalTrials.gov registry entry for NCT00838578 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT00838578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838578 about?
NCT00838578 is a clinical study titled "Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer". The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorect...
What is the current status of trial NCT00838578?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2009-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00838578?
The interventions under investigation include: Irinotecan (DRUG), KRN330 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00838578?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.